# Sreedar Subramanian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5498373/publications.pdf

Version: 2024-02-01

| 66 | 1,108 | 430874 18 | 414414 32 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 66 | 66 | 66 | 1927 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | How to manage: acute severe colitis. Frontline Gastroenterology, 2022, 13, 64-72. | 1.8 | 5 |
| 2 | Vitamin D, vitamin Dâ€"binding protein, free vitamin D and COVID-19 mortality in hospitalized patients. American Journal of Clinical Nutrition, 2022, 115, 1367-1377. | 4.7 | 12 |
| 3 | Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterology, 2022, 9, e000763. | 2.7 | 4 |
| 4 | Establishment of a validated central reading system for ileocolonoscopy in an academic setting. Gut, 2022, 71, 661-664. | 12.1 | 3 |
| 5 | Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study. Journal of Crohn's and Colitis, 2022, 16, 1436-1446. | 1.3 | 29 |
| 6 | Editorial: intravenous to subcutaneous vedolizumabâ€"switch without glitch!. Alimentary Pharmacology and Therapeutics, 2022, 56, 349-350. | 3.7 | 4 |
| 7 | Vitamin D and COVIDâ€19â€"Revisited. Journal of Internal Medicine, 2022, 292, 604-626. | 6.0 | 15 |
| 8 | Perspective: Vitamin D deficiency and COVIDâ€19 severity â€“ plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis. Journal of Internal Medicine, 2021, 289, 97-115. | 6.0 | 185 |
| 9 | From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. The Lancet Gastroenterology and Hepatology, 2021, 6, 88-89. | 8.1 | 26 |
| 10 | Unexpected cause of dysphagia. BMJ Case Reports, 2021, 14, e242339. | 0.5 | 0 |
| 11 | Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281. | 8.1 | 23 |
| 12 | P496 Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study. Journal of Crohn's and Colitis, 2021, 15, S480-S481. | 1.3 | 3 |
| 13 | Womenâ€™s Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. Patient, 2021, , . | 2.7 | 0 |
| 14 | Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 1236-1240. | 3.7 | 5 |
| 15 | Editorial: vedolizumab in inflammatory bowel diseasesâ€"less is more?. Alimentary Pharmacology and Therapeutics, 2021, 53, 443-444. | 3.7 | 2 |
| 16 | Letter: propensity scoreâ€"handle with care. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 362-363. | 3.7 | 0 |
| 17 | P272 Immune checkpoint inhibitor-related colitis assessment and prognosis: can inflammatory bowel disease scoring point the way?. Journal of Crohn's and Colitis, 2020, 14, S286-S288. | 1.3 | 1 |
| 18 | Recurrent colonic polyps. Gut, 2020, , gutjnl-2020-323133. | 12.1 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Vitamin D and COVID-19: evidence and recommendations for supplementation. Royal Society Open Science, 2020, 7, 201912. | 2.4 | 54 |
| 20 | Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with antiâ€TNFâ€refractory Crohnâ€™s disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1341-1352. | 3.7 | 46 |
| 21 | Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents. Journal of Crohn's and Colitis, 2020, 14, 1794-1795. | 1.3 | 2 |
| 22 | Ambulatory Management of Acute Severe Ulcerative Colitis: A Pandemic-driven Initiative. Inflammatory Bowel Diseases, 2020, 26, e112-e113. | 1.9 | 2 |
| 23 | Letter: low population mortality from COVIDâ€19 in countries south of latitude 35Â° North supports vitamin D as a factor determining severity. Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 412-413. | 3.7 | 18 |
| 24 | COVID-19 mortality increases with northerly latitude after adjustment for age suggesting a link with ultraviolet and vitamin D. BMJ Nutrition, Prevention and Health, 2020, 3, 118-120. | 3.7 | 41 |
| 25 | Editorial: endoscopic inflammation in ileoanal pouchesâ€”does it really matter?. Alimentary Pharmacology and Therapeutics, 2020, 51, 170-171. | 3.7 | 1 |
| 26 | Serum galectins as potential biomarkers of inflammatory bowel diseases. PLoS ONE, 2020, 15, e0227306. | 2.5 | 20 |
| 27 | From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohnâ€™s disease. Scandinavian Journal of Gastroenterology, 2020, 55, 148-153. | 1.5 | 1 |
| 28 | Editorial: low population mortality from COVIDâ€19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity. Alimentary Pharmacology and Therapeutics, 2020, 51, 1434-1437. | 3.7 | 202 |
| 29 | Infliximab in acute severe colitis: getting the right dose. Frontline Gastroenterology, 2020, 11, 427-429. | 1.8 | 3 |
| 30 | Letter: Covidâ€19â€”reâ€initiating clinical services for chronic gastrointestinal diseases. How and when?. Alimentary Pharmacology and Therapeutics, 2020, 52, 1414-1415. | 3.7 | 5 |
| 31 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |
| 32 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |
| 33 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |
| 34 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |
| 35 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |
| 36 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |
| 38 | Serum galectins as potential biomarkers of inflammatory bowel diseases. , 2020, 15, e0227306. | | 0 |
| 39 | Letter: population mortality from COVIDâ€19 and latitudeâ€”data from China. Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1261-1262. | 3.7 | 0 |
| 40 | Brief report: length of ileal resection correlates with severity of bile acid malabsorption in Crohnâ€™s disease. International Journal of Colorectal Disease, 2019, 34, 185-188. | 2.2 | 9 |
| 41 | P093 CD4 T-cell transcriptome analysis at baseline predicts clinical remission to anti-TNF agents in ulcerative colitis (UC). Journal of Crohn's and Colitis, 2019, 13, S132-S133. | 1.3 | 0 |
| 42 | P100 Real-world data: the incidence, diagnosis, and management outcomes of patients with immunotherapy-related colitis in two tertiary centres. Journal of Crohn's and Colitis, 2019, 13, S137-S138. | 1.3 | 2 |
| 43 | Infliximab induction regimens in steroidâ€refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Alimentary Pharmacology and Therapeutics, 2019, 50, 675-683. | 3.7 | 32 |
| 44 | Editorial: accelerated infliximab inductionâ€”it's time to settle the debate! Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 50, 1061-1062. | 3.7 | 0 |
| 45 | P423 Comparative efficacy of anti-tumour necrosis factor agents and vedolizumab in ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S321-S321. | 1.3 | 0 |
| 46 | P586 Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohnâ€™s disease: a multi-centre retrospective cohort study. Journal of Crohn's and Colitis, 2019, 13, S407-S408. | 1.3 | 1 |
| 47 | Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Digestive Diseases and Sciences, 2019, 64, 1119-1128. | 2.3 | 22 |
| 48 | Editorial: the <scp>IBD</scp>â€disability indexâ€”ready for prime time?. Alimentary Pharmacology and Therapeutics, 2018, 47, 298-299. | 3.7 | 0 |
| 49 | Editorial: mitigating primary nonresponse to infliximabâ€”are we better equipped now?. Alimentary Pharmacology and Therapeutics, 2018, 47, 434-435. | 3.7 | 0 |
| 50 | Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?. Gut, 2017, 66, 362-381. | 12.1 | 65 |
| 51 | PWE-062â€…Effectiveness and safety of vedolizumab (vdz) in ibd patients: a multicentre experience of â€˜real world dataâ€™ from the uk. , 2017, , . | | 0 |
| 52 | Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels. European Journal of Gastroenterology and Hepatology, 2016, 28, 271-276. | 1.6 | 28 |
| 53 | OC-072â€…The Toppic Trial: A Randomised, Double-Blind Parallel Group Trial of Mercaptopurine VS Placebo to Prevent Recurrence of Crohnâ€™s Disease Following Surgical Resection in 240 Patients. Gut, 2016, 65, A43.2-A44. | 12.1 | 3 |
| 54 | Validation of a Simple 0 to 10 Numerical Score (IBD-10) of Patient-reported Inflammatory Bowel Disease Activity for Routine Clinical Use. Inflammatory Bowel Diseases, 2016, 22, 1902-1907. | 1.9 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | PTH-070ÂPatients receiving anti-tnf agents for inflammatory bowel disease: exposure to diagnostic ionising radiation and trends in imaging modalities. Gut, 2015, 64, A437.1-A437. | 12.1 | 0 |
| 56 | PTU-335ÂQuality of care in the management of inflammatory bowel disease: how do patients rate their quality of care?: Abstract PTU-335 Table 1. Gut, 2015, 64, A209.2-A210. | 12.1 | 0 |
| 57 | Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2015, 9, 640-646. | 1.3 | 29 |
| 58 | PWE-091â€…Crohnâ€™s Disease Monocyte-derived Macrophages Exhibit Equivalent Responses To Intramacrophage Bacterial Infection Relative To Healthy Controls. Gut, 2014, 63, A163.2-A164. | 12.1 | 0 |
| 59 | PTU-068â€…Efficacy And Safety Of Granulocyte, Monocyte/macrophage Adsorptive Apheresis In Steroid-dependent Active Uc With Insufficient Response Or Intolerance To Immunosuppressants And/or Biological Therapies (the Art Trial): Week 12 Results. Gut, 2014, 63, A68.1-A68. | 12.1 | 0 |
| 60 | PWE-114â€…The Ibd-control Questionnaire: Multi-centre Validation Plus Evaluation In Routine Care. Gut, 2014, 63, A174.2-A175. | 12.1 | 2 |
| 61 | PWE-100â€…Increasing Weight And Body Mass Index Adversely Affect Thioguanine Nucleotide Levels In Inflammatory Bowel Disease: Abstract PWE-100 Table 1. Gut, 2014, 63, A168.1-A168. | 12.1 | 0 |
| 62 | PTH-171â€…Colonoscopy Performance in Extended Three Session Working Days. Gut, 2013, 62, A281.1-A281. | 12.1 | 1 |
| 63 | Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflammatory Bowel Diseases, 2011, 17, 99-104. | 1.9 | 38 |
| 64 | OC-009â€…Characterisation and outcome of patients with infliximab induced lupus erythematosus and retreatment with a second anti-tumour necrosis factor agent:. Gut, 2010, 59, A4.2-A4. | 12.1 | 0 |
| 65 | Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. Antimicrobial Agents and Chemotherapy, 2008, 52, 427-434. | 3.2 | 92 |
| 66 | Bacteria in the pathogenesis of inflammatory bowel disease. Current Opinion in Infectious Diseases, 2006, 19, 475-484. | 3.1 | 66 |